Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -20069.1%
Operating margin was -20069.1% in Q1 FY2026, down 17889.3 pp from a year earlier. On a trailing-twelve-month basis it was -168.0%, up 2215.9 pp year over year. Over 3 fiscal years it widened by 769.6 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 6 analysts of -15782.7% for the fiscal year ending Dec 2026, down from -154.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -20069.1%-20090.9 pp QoQ
- Last fiscal yearDec 2025
- -154.7%+2282.8 pp YoY
- LTMMar 2026
- -168.0%+2215.9 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -154.7%
- Year-over-year change
- +2282.8pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -154.7% | +2282.8pp |
| FY2024 | 2024-12-31 | -2437.5% | -571.3pp |
| FY2023 | 2023-12-31 | -1866.2% | -941.8pp |
| FY2022 | 2022-12-31 | -924.3% | -3711.9pp |
| FY2021 | 2021-12-31 | 2787.6% | — |
Operating Margin vs competitors
How OBIO compares with its peers on the latest reported figures
- OBIO's LTM Mar 2026 operating margin of -168.0% is the 3rd highest of the 9 companies compared; the peer median is -897.6%.
- Its year-over-year change of +2215.9 pp is the highest of 7, against a peer median of +163.7 pp.
- Over three fiscal years its change of +769.6 pp compares with a peer median of -1452.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -87.2% | +71.2 pp | +13.1 pp | |
| LTM Mar 2026 | -146.4% | +256.2 pp | — | |
| LTM Mar 2026 | -168.0% | +2215.9 pp | +769.6 pp | |
| LTM Mar 2026 | -503.2% | +1496.5 pp | — | |
| LTM Mar 2026 | -619.6% | — | — | |
| LTM Mar 2026 | -1175.7% | +473.1 pp | -452.3 pp | |
| FY2025 | -2921.0% | -1860.3 pp | -2452.0 pp | |
| LTM Mar 2026 | -38159.1% | — | — | |
| LTM Mar 2026 | -134164.4% | -122732.2 pp | -123394.3 pp | |
EPRXEupraxia Pharmaceuticals Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding OBIO) | -897.6% | +163.7 pp | -1452.2 pp | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | (782K) | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | 199K | 322K | 186K | 204K | 190K |
| Gross Profit | (981K) | 3.21M | 2.57M | 2.43M | 33.29M |
| Gross Margin | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| Research & Development | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| Selling, General & Admin | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| Operating Expenses | 20.82M | 35.87M | 54.08M | 66.74M | 85.1M |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| EBITDA | (21.91M) | (33.39M) | (48.83M) | (60.72M) | (51.23M) |
| EBITDA Margin | 2801.3% | -945.0% | -1769.3% | -2301.6% | -153.0% |
| Operating Income | (21.8M) | (32.66M) | (51.51M) | (64.3M) | (51.81M) |
| Operating Margin | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Interest Income | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 927K | 0 | 0 | 0 | 1.15M |
| Other Income / Expenses | (1.22M) | (951K) | 2.39M | 3.28M | (894K) |
| Income Before Tax | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Pre-Tax Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Net Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (Basic) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| EPS (Diluted) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| Weighted Avg Shares | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
| Weighted Avg Shares (Diluted) | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.